CR20230468A - Inhibidores de mk2 y usos de estos - Google Patents
Inhibidores de mk2 y usos de estosInfo
- Publication number
- CR20230468A CR20230468A CR20230468A CR20230468A CR20230468A CR 20230468 A CR20230468 A CR 20230468A CR 20230468 A CR20230468 A CR 20230468A CR 20230468 A CR20230468 A CR 20230468A CR 20230468 A CR20230468 A CR 20230468A
- Authority
- CR
- Costa Rica
- Prior art keywords
- disorders
- inhibitors
- compositions
- inflammatory
- inflammatory disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168407P | 2021-03-31 | 2021-03-31 | |
| US202263318118P | 2022-03-09 | 2022-03-09 | |
| PCT/US2022/022525 WO2022212489A1 (en) | 2021-03-31 | 2022-03-30 | Mk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230468A true CR20230468A (es) | 2023-12-07 |
Family
ID=83459911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230468A CR20230468A (es) | 2021-03-31 | 2022-03-30 | Inhibidores de mk2 y usos de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11680056B2 (https=) |
| EP (1) | EP4313970A4 (https=) |
| JP (1) | JP2024512154A (https=) |
| KR (1) | KR20230163501A (https=) |
| AU (1) | AU2022252242A1 (https=) |
| BR (1) | BR112023019861A2 (https=) |
| CA (1) | CA3215746A1 (https=) |
| CL (1) | CL2023002921A1 (https=) |
| CO (1) | CO2023013150A2 (https=) |
| CR (1) | CR20230468A (https=) |
| DO (1) | DOP2023000212A (https=) |
| IL (1) | IL307187A (https=) |
| MX (1) | MX2023011503A (https=) |
| PE (1) | PE20240144A1 (https=) |
| TW (1) | TW202304879A (https=) |
| WO (1) | WO2022212489A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| EP4367099A4 (en) | 2021-07-09 | 2025-06-04 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
| WO2023125708A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116444492B (zh) * | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116425722B (zh) * | 2022-01-13 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮-芳(杂)环类化合物及其制备方法与应用 |
| EP4464694A4 (en) * | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| WO2023217184A2 (zh) * | 2022-05-12 | 2023-11-16 | 上海美悦生物科技发展有限公司 | 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途 |
| TW202412792A (zh) * | 2022-08-30 | 2024-04-01 | 大陸商長春金賽藥業有限責任公司 | ｐ３８α－ＭＫ２抑制劑化合物、藥物組合物及其用途 |
| WO2024077059A1 (en) * | 2022-10-05 | 2024-04-11 | Xinthera, Inc. | Crystalline forms of an mk2 inhibitor |
| TW202428271A (zh) * | 2022-11-16 | 2024-07-16 | 大陸商上海美悦生物科技發展有限公司 | 吡啶氮氧化物類衍生物及其藥物組合物、製備方法和用途 |
| EP4650347A1 (en) * | 2023-01-13 | 2025-11-19 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| CN121368484A (zh) * | 2023-06-26 | 2026-01-20 | 深圳信立泰药业股份有限公司 | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE448784T1 (de) * | 2002-02-14 | 2009-12-15 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| US7183287B2 (en) * | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US20070167621A1 (en) * | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| CL2004002050A1 (es) * | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| CA2640665A1 (en) * | 2006-02-10 | 2007-08-16 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
| WO2008153942A1 (en) * | 2007-06-06 | 2008-12-18 | Xcovery, Inc. | Kinase inhibitor compounds |
| US20120077794A1 (en) | 2009-06-03 | 2012-03-29 | Glaxsmithkline Llc | Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
| SI2648516T1 (sl) | 2010-12-06 | 2019-01-31 | Aclaris Therapeutics, Inc. | Substituirane spojine piridinon-piridinila |
| US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| CN103930165B (zh) | 2011-09-02 | 2018-05-25 | 纽约市哥伦比亚大学理事会 | 用以治疗肥胖症的代谢紊乱的CaMKII、IP3R、钙调神经磷酸酶、P38和MK2/3抑制剂 |
| US9056110B2 (en) * | 2011-12-06 | 2015-06-16 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| US9365540B2 (en) * | 2012-01-12 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as MCH receptor antagonists |
| HUE054178T2 (hu) | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek |
| JP2022542434A (ja) | 2019-07-31 | 2022-10-03 | アクラリス セラピューティクス，インコーポレイテッド | 重水素化ｍｋ２経路阻害剤およびその使用方法 |
| KR20220161396A (ko) | 2020-03-27 | 2022-12-06 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형 |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| EP4247380A4 (en) | 2020-11-23 | 2025-03-05 | Aclaris Therapeutics, Inc. | PROCESSES FOR THE SYNTHESIS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS |
| CN116670142A (zh) | 2021-02-01 | 2023-08-29 | 细胞基因公司 | Mk2抑制剂、其合成和其中间体 |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| EP4685147A3 (en) | 2021-03-31 | 2026-04-15 | Fedora Pharmaceuticals Inc. | Lactivicin compounds, their preparation and use as antibacterial agents |
| PY2222114A (es) | 2021-03-31 | 2023-01-19 | Syngenta Crop Protection Ag | Derivados microbiocidas de quinolin/quinoxalin-benzotiazina |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| PE20250262A1 (es) | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| TW202317573A (zh) | 2021-06-30 | 2023-05-01 | 美商凱麥拉醫療公司 | Mk2降解劑及其用途 |
| EP4367099A4 (en) | 2021-07-09 | 2025-06-04 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
| WO2023001282A1 (zh) | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| TW202315625A (zh) | 2021-08-13 | 2023-04-16 | 大陸商深圳信立泰藥業股份有限公司 | 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途 |
| CN116178345B (zh) | 2021-10-19 | 2024-08-13 | 深圳信立泰药业股份有限公司 | 一种取代的嘧啶基-吡啶基-吡啶酮化合物及其制备方法与应用 |
| WO2023125708A1 (zh) | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116444492B (zh) | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN115636814A (zh) | 2022-02-28 | 2023-01-24 | 瑞石生物医药有限公司 | 一种嘧啶衍生物及其用途 |
-
2022
- 2022-03-30 BR BR112023019861A patent/BR112023019861A2/pt not_active Application Discontinuation
- 2022-03-30 JP JP2023560811A patent/JP2024512154A/ja active Pending
- 2022-03-30 TW TW111112312A patent/TW202304879A/zh unknown
- 2022-03-30 WO PCT/US2022/022525 patent/WO2022212489A1/en not_active Ceased
- 2022-03-30 EP EP22782084.2A patent/EP4313970A4/en active Pending
- 2022-03-30 CR CR20230468A patent/CR20230468A/es unknown
- 2022-03-30 IL IL307187A patent/IL307187A/en unknown
- 2022-03-30 AU AU2022252242A patent/AU2022252242A1/en active Pending
- 2022-03-30 KR KR1020237037138A patent/KR20230163501A/ko active Pending
- 2022-03-30 PE PE2023002765A patent/PE20240144A1/es unknown
- 2022-03-30 CA CA3215746A patent/CA3215746A1/en active Pending
- 2022-03-30 MX MX2023011503A patent/MX2023011503A/es unknown
- 2022-07-19 US US17/868,567 patent/US11680056B2/en active Active
-
2023
- 2023-05-02 US US18/310,943 patent/US12545662B2/en active Active
- 2023-07-13 US US18/352,078 patent/US11987574B2/en active Active
- 2023-09-29 DO DO2023000212A patent/DOP2023000212A/es unknown
- 2023-09-29 CL CL2023002921A patent/CL2023002921A1/es unknown
- 2023-10-02 CO CONC2023/0013150A patent/CO2023013150A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240144A1 (es) | 2024-02-01 |
| JP2024512154A (ja) | 2024-03-18 |
| US11987574B2 (en) | 2024-05-21 |
| WO2022212489A1 (en) | 2022-10-06 |
| CL2023002921A1 (es) | 2024-04-01 |
| BR112023019861A2 (pt) | 2023-11-07 |
| IL307187A (en) | 2023-11-01 |
| US20230265076A1 (en) | 2023-08-24 |
| EP4313970A1 (en) | 2024-02-07 |
| MX2023011503A (es) | 2023-10-19 |
| US11680056B2 (en) | 2023-06-20 |
| US20230373969A1 (en) | 2023-11-23 |
| EP4313970A4 (en) | 2025-06-25 |
| US12545662B2 (en) | 2026-02-10 |
| TW202304879A (zh) | 2023-02-01 |
| AU2022252242A1 (en) | 2023-10-05 |
| DOP2023000212A (es) | 2023-11-30 |
| US20220402892A1 (en) | 2022-12-22 |
| KR20230163501A (ko) | 2023-11-30 |
| CA3215746A1 (en) | 2022-10-06 |
| CO2023013150A2 (es) | 2024-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011503A (es) | Inhibidores de mk2 y usos de estos. | |
| MX2025004367A (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| PH12021552856A1 (en) | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | |
| EP4234551A3 (en) | Pyridazinones as parp7 inhibitors | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| MX2025006196A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso | |
| ZA202206482B (en) | Substituted macrocyclic compounds and related methods of treatment | |
| EA202190377A9 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
| MY205416A (en) | Tyk2 inhibitors and uses thereof | |
| CO2021001472A2 (es) | Inhibidores de transglutaminasa 2 (tg2) | |
| GEP20237508B (en) | Combination product of bcl-2 inhibitor or bcl-2/bcl-xl dual inhibitor and btk inhibitor and use thereof in the prevention and/or treatment of diseases | |
| EP3612215A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF Pneumonia | |
| PH12017501669A1 (en) | Alpha-cinnamide compounds and compositions as hdac8 inhibitors | |
| WO2016141108A8 (en) | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| EP4691567A3 (en) | Jak1 pathway inhibitor for use in the treatment of chronic lung allograft dysfunction | |
| MX2020011065A (es) | Inhibidores stat3. | |
| BR112021008200A2 (pt) | Composições e métodos para distúrbios de alfa-1-antitripsina | |
| PH12020550537A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| ZA202200266B (en) | Composition for prostaglandin transporter inhibition and related therapeutic applications | |
| EA202090424A1 (ru) | Бициклические ингибиторы гистондеацетилазы | |
| BR112021019448A2 (pt) | Métodos para o tratamento de beta-talassemia | |
| PH12020552202A1 (en) | Antibody molecules to complement component 5 and uses thereof | |
| EA202193086A1 (ru) | Ингибиторы аутофагии на основе фениламинопиримидинамида и способы их применения | |
| TW202615427A (zh) | 胺基嘧啶醯胺自噬作用抑制劑及其使用方法 |